CN102264733B - 新型多巴胺d3受体配体，其制备方法及其医药用途 - Google Patents

新型多巴胺d3受体配体，其制备方法及其医药用途 Download PDF

Info

Publication number
CN102264733B
CN102264733B CN200980139777.3A CN200980139777A CN102264733B CN 102264733 B CN102264733 B CN 102264733B CN 200980139777 A CN200980139777 A CN 200980139777A CN 102264733 B CN102264733 B CN 102264733B
Authority
CN
China
Prior art keywords
compound
formula
piperazinyl
carboxamide
benzo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200980139777.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN102264733A (zh
Inventor
李锦�
杨日芳
宋睿
祝辉
吴宁
恽榴红
苏瑞斌
赵如胜
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institute of Pharmacology and Toxicology of AMMS
Original Assignee
Institute of Pharmacology and Toxicology of AMMS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute of Pharmacology and Toxicology of AMMS filed Critical Institute of Pharmacology and Toxicology of AMMS
Priority to CN200980139777.3A priority Critical patent/CN102264733B/zh
Publication of CN102264733A publication Critical patent/CN102264733A/zh
Application granted granted Critical
Publication of CN102264733B publication Critical patent/CN102264733B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
CN200980139777.3A 2008-10-10 2009-09-28 新型多巴胺d3受体配体，其制备方法及其医药用途 Active CN102264733B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN200980139777.3A CN102264733B (zh) 2008-10-10 2009-09-28 新型多巴胺d3受体配体，其制备方法及其医药用途

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN200810167089.5 2008-10-10
CN200810167089 2008-10-10
PCT/CN2009/001096 WO2010040274A1 (zh) 2008-10-10 2009-09-28 新型多巴胺d3受体配体，其制备方法及其医药用途
CN200980139777.3A CN102264733B (zh) 2008-10-10 2009-09-28 新型多巴胺d3受体配体，其制备方法及其医药用途

Publications (2)

Publication Number Publication Date
CN102264733A CN102264733A (zh) 2011-11-30
CN102264733B true CN102264733B (zh) 2014-07-30

Family

ID=42100196

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980139777.3A Active CN102264733B (zh) 2008-10-10 2009-09-28 新型多巴胺d3受体配体，其制备方法及其医药用途

Country Status (5)

Country Link
US (1) US8829001B2 (enExample)
EP (1) EP2354136B1 (enExample)
JP (1) JP5701213B2 (enExample)
CN (1) CN102264733B (enExample)
WO (1) WO2010040274A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9227944B2 (en) * 2008-10-10 2016-01-05 Institute Of Pharmacology And Toxicology Academy Of Military Science P.L.A. China Dopamine D3 receptor ligands and preparation and medical uses of the same
CN103073524B (zh) * 2013-01-25 2015-06-10 宁波市微循环与莨菪类药研究所 4-[4-(取代苯基)哌嗪基-1]-丁胺甲酸取代芳香酯衍生物及其制备方法
AR094929A1 (es) 2013-02-28 2015-09-09 Bristol Myers Squibb Co Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2
CN105102448B (zh) 2013-02-28 2018-03-06 百时美施贵宝公司 作为rock1和rock2抑制剂的苯基吡唑衍生物
CN105461608B (zh) * 2015-11-23 2017-11-28 东南大学 二氢吲哚‑2‑酮类d3受体配体及其制备方法和用途
EP3495363B1 (en) 2016-07-28 2023-08-23 Shionogi & Co., Ltd Nitrogen-containing condensed ring compounds having dopamine d3 receptor antagonistic effect
CN109419802B (zh) * 2017-08-28 2023-01-13 中国人民解放军军事医学科学院毒物药物研究所 具有多巴胺d3受体调节活性的化合物及其用途
CN108329282B (zh) * 2018-01-16 2022-01-07 新乡医学院 一种苯基哌嗪类衍生物及其制备方法和应用
WO2019146740A1 (ja) 2018-01-26 2019-08-01 塩野義製薬株式会社 ドーパミンｄ３受容体拮抗作用を有する環式化合物
KR20200112910A (ko) 2018-01-26 2020-10-05 시오노기 앤드 컴파니, 리미티드 도파민 d3 수용체 길항 작용을 갖는 축환 화합물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1665503A (zh) * 2002-07-04 2005-09-07 施瓦茨制药有限公司 杂芳烃甲酰胺作为多巴胺－d3配体用于治疗中枢神经系统疾病的用途
CN101027294A (zh) * 2004-12-30 2007-08-29 施瓦茨制药有限公司 作为多巴胺d3拮抗剂的含氧的稠合的苯基哌嗪－和苯基diazepan羧酰胺
CN101084225A (zh) * 2004-11-26 2007-12-05 詹森药业有限公司 具有改良的抗精神病和抗焦虑活性的异唑啉－吲哚衍生物

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2613365B1 (fr) 1987-04-01 1989-07-28 Adir Nouveaux derives de l'amino tetrahydro-5, 6, 7, 8 naphto (2, 3b) furanne, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent
US5656762A (en) 1990-12-28 1997-08-12 Neurogen Corporation 4-piperidino-and piperazinomethyl-2-phenylimidazole derivatives, dopamine receptor subtype specific ligands
AU7513494A (en) 1993-08-06 1995-02-28 Upjohn Company, The 2-aminoindans as selective dopamine d3 ligands
US6756388B1 (en) 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
DE4425146A1 (de) * 1994-07-15 1996-01-18 Basf Ag Verwendung heterocyclischer Verbindungen
FR2742149B1 (fr) 1995-12-11 1998-02-13 Inst Nat Sante Rech Med Nouveaux derives de 2-naphtamides et leurs applications therapeutiques
IL126747A0 (en) 1996-05-11 1999-08-17 Smithkline Beecham Plc Tetrahydroisoquinoline derivatives as modulators of dopamine D3 receptors
US6143762A (en) 1996-08-14 2000-11-07 Smithkline Beecham, Plc Tetrahydroisoquinoline derivatives and their pharmaceutical use
JP2002501506A (ja) 1997-05-03 2002-01-15 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー ドーパミンｄ▲下３▼受容体のモジュレーターとしてのテトラヒドロイソキノリン誘導体
GB9821978D0 (en) 1998-10-08 1998-12-02 Smithkline Beecham Plc Compounds
AR022230A1 (es) 1999-01-12 2002-09-04 Abbott Gmbh & Co Kg Compuestos de triazol, composicion farmaceutica que los comprende y uso de los mismos para preparar dicha composicion
KR20030068164A (ko) 2000-11-30 2003-08-19 랜박시 래보러터리스 리미티드 우로-선택성 α1-아드레날린 수용체 차단제로 유용한1,4-이치환된 피페라진 유도체
KR100394083B1 (ko) 2000-12-04 2003-08-06 학교법인 성신학원 도파민 ｄ3 및 ｄ4 수용체의 선택적 활성을 지닌 신규4,5-디히드로이소옥사졸릴알킬피페라진 유도체와, 이의제조방법
HUP0103987A3 (en) 2001-09-28 2004-11-29 Richter Gedeon Vegyeszet Phenylpiperazinylalkyl carboxylic acid amid derivatives, process for their preparation, pharmaceutical compositions containing them and their intermediates
GB0130219D0 (en) 2001-12-18 2002-02-06 Pfizer Ltd Compounds for the treatment of sexual dysfunction
DE10232020A1 (de) 2002-07-04 2004-02-26 Friedrich-Alexander-Universität Erlangen-Nürnberg Neurorezeptoraktive Heteroarencarboxamide
US20040204422A1 (en) 2003-04-14 2004-10-14 Abbott Gmbh & Co. Kg. N-[(Piperazinyl)hetaryl]arylsulfonamide compounds
JP4904267B2 (ja) 2004-08-09 2012-03-28 アボット ゲーエムベーハー ウント カンパニー カーゲー ドーパミンｄ３受容体の調節に応答する障害の治療に好適な４−ピペラジニル−ピリミジン化合物
FR2878524B1 (fr) 2004-12-01 2007-01-19 Bioprojet Soc Civ Ile Nouveaux derives d'arylpiperazine
GB0517187D0 (en) 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
TW200831498A (en) * 2006-10-13 2008-08-01 Otsuka Pharma Co Ltd Heterocyclic compound
JP2008115175A (ja) * 2006-10-13 2008-05-22 Otsuka Pharmaceut Co Ltd 複素環化合物
EP2184272A4 (en) * 2007-08-21 2011-11-09 Shionogi & Co PIPERAZINE DERIVATIVE

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1665503A (zh) * 2002-07-04 2005-09-07 施瓦茨制药有限公司 杂芳烃甲酰胺作为多巴胺－d3配体用于治疗中枢神经系统疾病的用途
CN101084225A (zh) * 2004-11-26 2007-12-05 詹森药业有限公司 具有改良的抗精神病和抗焦虑活性的异唑啉－吲哚衍生物
CN101027294A (zh) * 2004-12-30 2007-08-29 施瓦茨制药有限公司 作为多巴胺d3拮抗剂的含氧的稠合的苯基哌嗪－和苯基diazepan羧酰胺

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Design, Synthesis, and Binding Affinities of Potential Positron Emission Tomography(PET) Ligands for visualization of Brain Dopamine D3 Receptors;Marcello Leopoldo，等;《Journal of Medicinal Chemistry》;20051122;第49卷(第1期);358-365 *
Heterocyclic Analogues of N-(4-(4-(2,3-Dichlorophenyl)piperazin-1-yl)butyl)arylcarboxamides with Functionalized Linking Chains as Novel Dopamine D3 Receptor Ligands: Potential Substance Abuse Therapeutic Agents;Peter Grundt，等;《Journal of Medicinal Chemistry》;20070802;第50卷(第17期);4135-4146 *

Also Published As

Publication number Publication date
US8829001B2 (en) 2014-09-09
JP5701213B2 (ja) 2015-04-15
US20110319423A1 (en) 2011-12-29
JP2012505165A (ja) 2012-03-01
CN102264733A (zh) 2011-11-30
WO2010040274A1 (zh) 2010-04-15
EP2354136A1 (en) 2011-08-10
EP2354136A4 (en) 2012-04-18
EP2354136B1 (en) 2016-02-24

Similar Documents

Publication Publication Date Title
CN102264733B (zh) 新型多巴胺d3受体配体，其制备方法及其医药用途
KR101890441B1 (ko) P2x4 수용체 길항제
CN100457731C (zh) 代谢型谷氨酸受体的苯甲酰胺调节剂
JP2003528096A (ja) デカヒドロ−イソキノリン
KR19990028757A (ko) 벤조[ｇ]퀴놀린 유도체
JP2012505165A5 (enExample)
KR101463190B1 (ko) ５­ｈｔ６ 수용체 리간드인 술폰 화합물
JP2002525373A (ja) ２−ピペラジノアルキルアミノベンゾアゾール誘導体：ドーパミン受容体サブタイプ特殊リガンド
EP0841330B1 (fr) Nouveaux dérivés aminométhyl hétérocycliques, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
TWI495640B (zh) 苯並氮呯化合物
AU2008315309B2 (en) Amino arylsulfonamide compounds and their use as 5-HT6 ligands
FR2558835A1 (fr) Derives d'hydantoine, leur procede de production et medicament les contenant
JP2018087173A (ja) 悪性脳腫瘍治療薬
US9227944B2 (en) Dopamine D3 receptor ligands and preparation and medical uses of the same
IE871154L (en) Quinoline-4-oxime derivatives
CA2737282C (en) Aryl sulfonamide amine compounds and their use as 5-ht6 ligands
US6960611B2 (en) Sulfonyl-containing 2,3-diarylindole compounds, methods for making same, and methods of use thereof
CN105461608B (zh) 二氢吲哚‑2‑酮类d3受体配体及其制备方法和用途
CN109419802B (zh) 具有多巴胺d3受体调节活性的化合物及其用途
EP3178810A1 (en) Condensed heterocyclic compound
KR101459720B1 (ko) 세로토닌 5-ＨＴ6 저해 활성을 갖는 5-설포닐아미노-5,6-다이하이드로-1Ｈ-피라졸로[3,4-ｃ]피리딘-7(4Ｈ)-온 화합물
CN104710358A (zh) 喹啉-4-甲酰胺衍生物及其医药用途
CN103459371A (zh) 芳基丙烯酰胺化合物及其用于制备免疫抑制剂的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant